Hiroshi Fukui1. 1. Department of Gastroenterology, Endocrinology and Metabolism, Nara Medical University, Kashihara, Japan.
Abstract
BACKGROUND: Increased intestinal permeability due to barrier dysfunction is supposed to cause microbial translocation which may induce low-grade inflammation in various diseases. However, this series of events has not been comprehensively evaluated yet. SUMMARY: Intestinal epithelial barrier dysfunction and increased permeability have been described in patients with inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), alcoholic liver disease, nonalcoholic steatohepatitis (NASH), liver cirrhosis, acute pancreatitis, primary biliary cholangitis (PBC), type 1 and type 2 diabetes, chronic kidney disease, chronic heart failure (CHF), depression, and other diseases. Most clinical reports used either permeability assays of challenge tests or measurement of circulating bacterial markers like endotoxin for assessment of 'the leaky gut'. The intestinal permeability assessed by the challenge tests has often been related to the changes of tight junction proteins in the epithelium or circulating endotoxin levels. In patients with IBD, alcoholic liver disease, NASH, liver cirrhosis, PBC, obstructive jaundice, severe acute pancreatitis, and CHF, endotoxemia and proinflammatory cytokinemia have been found in addition to increased permeability. In the serum of patients with IBS and depression, antiflagellin antibodies and antilipid A antibodies were detected, respectively, together with increased permeability and proinflammatory cytokinemia. The site of infection, which is localized to the intestine in IBD and IBS, includes various extraintestinal organs in other diseases. The relation of gut dysbiosis to intestinal barrier dysfunction has gradually been clarified. KEY MESSAGES: Although no direct cause-and-effect relationship has been confirmed, all clinical and experimental data suggest the importance of intestinal hyperpermeability in the inflammatory changes of various diseases. Increased intestinal permeability is a new target for disease prevention and therapy. Considering the close relationship of 'the leaky gut' and gut dysbiosis to the major diseases, we can conclude that meticulous dietetic and probiotic approaches to recover healthy microbiota have the potential to make a breakthrough in the management of these diseases tomorrow.
BACKGROUND: Increased intestinal permeability due to barrier dysfunction is supposed to cause microbial translocation which may induce low-grade inflammation in various diseases. However, this series of events has not been comprehensively evaluated yet. SUMMARY: Intestinal epithelial barrier dysfunction and increased permeability have been described in patients with inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), alcoholic liver disease, nonalcoholic steatohepatitis (NASH), liver cirrhosis, acute pancreatitis, primary biliary cholangitis (PBC), type 1 and type 2 diabetes, chronic kidney disease, chronic heart failure (CHF), depression, and other diseases. Most clinical reports used either permeability assays of challenge tests or measurement of circulating bacterial markers like endotoxin for assessment of 'the leaky gut'. The intestinal permeability assessed by the challenge tests has often been related to the changes of tight junction proteins in the epithelium or circulating endotoxin levels. In patients with IBD, alcoholic liver disease, NASH, liver cirrhosis, PBC, obstructive jaundice, severe acute pancreatitis, and CHF, endotoxemia and proinflammatory cytokinemia have been found in addition to increased permeability. In the serum of patients with IBS and depression, antiflagellin antibodies and antilipid A antibodies were detected, respectively, together with increased permeability and proinflammatory cytokinemia. The site of infection, which is localized to the intestine in IBD and IBS, includes various extraintestinal organs in other diseases. The relation of gut dysbiosis to intestinal barrier dysfunction has gradually been clarified. KEY MESSAGES: Although no direct cause-and-effect relationship has been confirmed, all clinical and experimental data suggest the importance of intestinal hyperpermeability in the inflammatory changes of various diseases. Increased intestinal permeability is a new target for disease prevention and therapy. Considering the close relationship of 'the leaky gut' and gut dysbiosis to the major diseases, we can conclude that meticulous dietetic and probiotic approaches to recover healthy microbiota have the potential to make a breakthrough in the management of these diseases tomorrow.
Authors: J Niebauer; H D Volk; M Kemp; M Dominguez; R R Schumann; M Rauchhaus; P A Poole-Wilson; A J Coats; S D Anker Journal: Lancet Date: 1999-05-29 Impact factor: 79.321
Authors: Torfay Sharifnia; Joseph Antoun; Thomas G C Verriere; Giovanni Suarez; Julia Wattacheril; Keith T Wilson; Richard M Peek; Naji N Abumrad; Charles R Flynn Journal: Am J Physiol Gastrointest Liver Physiol Date: 2015-06-25 Impact factor: 4.052
Authors: Sophie Leclercq; Sébastien Matamoros; Patrice D Cani; Audrey M Neyrinck; François Jamar; Peter Stärkel; Karen Windey; Valentina Tremaroli; Fredrik Bäckhed; Kristin Verbeke; Philippe de Timary; Nathalie M Delzenne Journal: Proc Natl Acad Sci U S A Date: 2014-10-06 Impact factor: 11.205
Authors: Luzia Valentini; Sara Ramminger; Verena Haas; Elisa Postrach; Martina Werich; André Fischer; Michael Koller; Alexander Swidsinski; Stefan Bereswill; Herbert Lochs; Jörg-Dieter Schulzke Journal: Physiol Rep Date: 2014-04-22
Authors: Ninell P Mortensen; Maria Moreno Caffaro; Purvi R Patel; Md Jamal Uddin; Shyam Aravamudhan; Susan J Sumner; Timothy R Fennell Journal: NanoImpact Date: 2020-02-13
Authors: Jelena Todoric; Giuseppe Di Caro; Saskia Reibe; Darren C Henstridge; Courtney R Green; Alison Vrbanac; Fatih Ceteci; Claire Conche; Reginald McNulty; Shabnam Shalapour; Koji Taniguchi; Peter J Meikle; Jeramie D Watrous; Rafael Moranchel; Mahan Najhawan; Mohit Jain; Xiao Liu; Tatiana Kisseleva; Maria T Diaz-Meco; Jorge Moscat; Rob Knight; Florian R Greten; Lester F Lau; Christian M Metallo; Mark A Febbraio; Michael Karin Journal: Nat Metab Date: 2020-08-24
Authors: Manoj Kumar; Parul Singh; Selvasankar Murugesan; Marie Vetizou; John McCulloch; Jonathan H Badger; Giorgio Trinchieri; Souhaila Al Khodor Journal: Methods Mol Biol Date: 2020
Authors: Eemeli Jämsen; Jukka Pajarinen; Vesa-Petteri Kouri; Antti Rahikkala; Stuart B Goodman; Mikko Manninen; Dan C Nordström; Kari K Eklund; Katariina Nurmi Journal: Acta Biomater Date: 2020-03-17 Impact factor: 8.947